Prometheus Biosciences Incorporated develops and commercializes novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases. Its lead product is PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trials for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. Prometheus Biosciences was incorporated in 2016 and is headquartered in San Diego, CA.
What is Prometheus Biosciences's quote symbol?
What is the 52 week high and low for Prometheus Biosciences (NASDAQ: RXDX)?
How much is Prometheus Biosciences stock worth today?
How much is Prometheus Biosciences's stock price per share?
What is Prometheus Biosciences's Market Cap?